Cormorant Asset Management, LP — 13F Holdings & Portfolio
CIK 1583977 · latest 13F-HR filed 2026-08-14
Cormorant Asset Management, LP manages $1.95B in 13F-reported U.S. long-equity assets across 50 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are PRAX (10.98%), BBOT (6.98%), PBLS (6.47%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 13 new positions, exited 9, added to 11, and trimmed 23.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
50TH FLOOR
BOSTON, MA 02116
$1.95B
Long-equity book
50
Distinct positions
2026-06-30
Filed 2026-08-14
+13 / −9 / ↑11 / ↓23
vs 2026-03-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- ADLAI NORTYE LTD$25.7M +128.1%
- ORUKA THERAPEUTICS INC$24.6M +94.0%
- BIOHAVEN LTD$23.9M +160.8%
- RAPPORT THERAPEUTICS INC$18.2M +19.7%
- ERASCA INC$16.1M +17.1%
Top Trims
- PRAXIS PRECISION MEDICINES I-$71.0M -24.9%
- OLEMA PHARMACEUTICALS INC-$31.3M -53.7%
- BRIDGEBIO ONCOLOGY THERAPEUT-$23.8M -14.9%
- INSMED INC-$23.1M -74.3%
- BRIDGEBIO PHARMA INC-$22.2M -35.1%
New Positions
- PARABILIS MEDICINES INC$126.3M
- CLIMB BIO INC$27.5M
- SPYRE THERAPEUTICS INC$20.0M
- DEFINIUM THERAPEUTICS INC$18.8M
- ASCENDIS PHARMA A/S$13.3M
Exited Positions
- CENTESSA PHARMACEUTICALS PLC$41.7M
- MAZE THERAPEUTICS INC$22.4M
- ASCENDIS PHARMA A/S$21.7M
- TERNS PHARMACEUTICALS INC$15.8M
- ZURA BIO LTD$8.6M
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | PRAXIS PRECISION MEDICINES I | PRAX | 74006W207 | $214.3M | 10.98% | 640,000 | SH |
| 2 | BRIDGEBIO ONCOLOGY THERAPEUT | BBOT | 107924102 | $136.2M | 6.98% | 17,878,594 | SH |
| 3 | PARABILIS MEDICINES INC | PBLS | 698955101 | $126.3M | 6.47% | 4,615,612 | SH |
| 4 | RAPPORT THERAPEUTICS INC | RAPP | 75383L102 | $110.7M | 5.67% | 2,657,521 | SH |
| 5 | ERASCA INC | ERAS | 29479A108 | $109.9M | 5.63% | 6,000,000 | SH |
| 6 | EDGEWISE THERAPEUTICS INC | EWTX | 28036F105 | $102.0M | 5.23% | 2,510,000 | SH |
| 7 | EYEPOINT INC | EYPT | 30233G209 | $100.1M | 5.13% | 7,000,000 | SH |
| 8 | ALUMIS INC | ALMS | 022307102 | $92.5M | 4.74% | 3,285,596 | SH |
| 9 | ABIVAX SA | ABVX | 00370M103 | $90.0M | 4.61% | 675,000 | SH |
| 10 | DIANTHUS THERAPEUTICS INC | DNTH | 252828108 | $73.1M | 3.75% | 750,000 | SH |
| 11 | BRIGHT MINDS BIOSCIENCES INC | DRUG | 10919W405 | $63.2M | 3.24% | 900,000 | SH |
| 12 | MOONLAKE IMMUNOTHERAPEUTICS | MLTX | 61559X104 | $62.4M | 3.20% | 3,205,433 | SH |
| 13 | BIOAGE LABS INC | BIOA | 09077V100 | $58.6M | 3.00% | 2,390,605 | SH |
| 14 | ORUKA THERAPEUTICS INC | ORKA | 687604108 | $50.8M | 2.60% | 533,340 | SH |
| 15 | ADLAI NORTYE LTD | ANL | 00704R109 | $45.7M | 2.34% | 3,978,229 | SH |
| 16 | BRIDGEBIO PHARMA INC | BBIO | 10806X102 | $41.0M | 2.10% | 550,000 | SH |
| 17 | TANGO THERAPEUTICS INC | TNGX | 87583X109 | $40.6M | 2.08% | 1,300,000 | SH |
| 18 | BIOHAVEN LTD | BHVN | G1110E107 | $38.8M | 1.99% | 2,610,000 | SH |
| 19 | AGOMAB THERAPEUTICS NV | AGMB | 00860C102 | $32.0M | 1.64% | 2,465,348 | SH |
| 20 | MBX BIOSCIENCES INC | MBX | 55287L101 | $30.4M | 1.56% | 550,000 | SH |
| 21 | CLIMB BIO INC | CLYM | 28658R106 | $27.5M | 1.41% | 2,106,000 | SH |
| 22 | OLEMA PHARMACEUTICALS INC | OLMA | 68062P106 | $26.9M | 1.38% | 2,150,000 | SH |
| 23 | DAMORA THERAPEUTICS INC | DMRA | 36322Q206 | $26.0M | 1.33% | 1,000,000 | SH |
| 24 | PHARVARIS N V | PHVS | N69605108 | $25.9M | 1.33% | 750,000 | SH |
| 25 | CORBUS PHARMACEUTICALS HLDGS | CRBP | 21833P301 | $22.0M | 1.13% | 2,344,971 | SH |
| 26 | SPYRE THERAPEUTICS INC | SYRE | 00773J202 | $20.0M | 1.02% | 225,000 | SH |
| 27 | DEFINIUM THERAPEUTICS INC | DFTX | 24477V105 | $18.8M | 0.96% | 400,000 | SH |
| 28 | NEWAMSTERDAM PHARMA COMPANY | NAMS | N62509109 | $16.9M | 0.87% | 500,000 | SH |
| 29 | ROIVANT SCIENCES LTD | ROIV | G76279101 | $16.8M | 0.86% | 475,000 | SH |
| 30 | CABALETTA BIO INC | CABA | 12674W109 | $15.6M | 0.80% | 5,000,000 | SH |
| 31 | HELIX ACQUISITION CORP III | HLXC | G4444S107 | $13.8M | 0.71% | 1,297,500 | SH |
| 32 | ASCENDIS PHARMA A/S | ASND | K08588103 | $13.3M | 0.68% | 50,000 | SH |
| 33 | KAILERA THERAPEUTICS INC | KLRA | 482931102 | $12.1M | 0.62% | 550,000 | SH |
| 34 | INSMED INC | INSM | 457669307 | $8.0M | 0.41% | 75,000 | SH |
| 35 | FAETH THERAPEUTICS INC | FTH | 81728A207 | $7.7M | 0.39% | 1,028,242 | SH |
| 36 | ENLIVEN THERAPEUTICS INC | ELVN | 29337E102 | $7.6M | 0.39% | 150,000 | SH |
| 37 | TARSUS PHARMACEUTICALS INC | TARS | 87650L103 | $6.3M | 0.32% | 100,000 | SH |
| 38 | IBIO INC | IBIO | 451033708 | $6.2M | 0.32% | 3,570,000 | SH |
| 39 | CRINETICS PHARMACEUTICALS IN | CRNX | 22663K107 | $4.7M | 0.24% | 125,000 | SH |
| 40 | ARCUTIS BIOTHERAPEUTICS INC | ARQT | 03969K108 | $4.6M | 0.24% | 175,000 | SH |
| 41 | ARROWHEAD PHARMACEUTICALS IN | ARWR | 04280A100 | $4.1M | 0.21% | 50,000 | SH |
| 42 | STRUCTURE THERAPEUTICS INC | GPCR | 86366E106 | $4.0M | 0.21% | 75,000 | SH |
| 43 | RESEARCH ALLIANCE CORP III | RACC | G75226103 | $4.0M | 0.20% | 370,000 | SH |
| 44 | COGENT BIOSCIENCES INC | COGT | 19240Q201 | $3.9M | 0.20% | 100,000 | SH |
| 45 | ALTIMMUNE INC | ALT | 02155H200 | $3.8M | 0.19% | 1,250,000 | SH |
| 46 | AMYLYX PHARMACEUTICALS INC | AMLX | 03237H101 | $3.6M | 0.18% | 200,000 | SH |
| 47 | ODYSSEY THERAPEUTICS INC | ODTX | 67613T104 | $3.3M | 0.17% | 175,000 | SH |
| 48 | VAXCYTE INC | PCVX | 92243G108 | $2.9M | 0.15% | 50,000 | SH |
| 49 | BOUNDLESS BIO INC | BOLD | 10170A100 | $2.5M | 0.13% | 1,000,000 | SH |
| 50 | QUINCE THERAPEUTICS INC | QNCX | 22053A305 | $100.0K | 0.01% | 5,498 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-14 | $1.95B | 50 | 0001583977-26-000007 |
| 2026-03-31 | 2026-05-15 | $1.99B | 47 | 0001583977-26-000002 |
| 2025-12-31 | 2026-02-17 | $2.16B | 35 | 0001583977-26-000001 |
| 2025-09-30 | 2025-11-14 | $1.45B | 36 | 0001583977-25-000011 |